Pharmaceutical - AbbVie

Filter

Current filters:

AbbVie

Popular Filters

1 to 25 of 86 results

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

Shire gets priority review for its Vyvanse sNDA in binge eating from FDA

15-09-2014

Ireland-headquartered drugmaker Shire has received acceptance for its filing with priority review for…

AbbVieIrelandNeurologicalPharmaceuticalRegulationShireVyvanse

Positive new data for AbbVie’s Humira in HS

Positive new data for AbbVie’s Humira in HS

11-09-2014

US pharma group AbbVie has released results from a Phase III pivotal study demonstrating that its blockbuster…

AbbVieAnti-Arthritics/RheumaticsDermatologicalsHumiraPharmaceuticalResearch

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

Infinity and AbbVie collaborate on duvelisib in deal worth up to $805 million

03-09-2014

US drug discovery firm Infinity Pharmaceuticals has entered into a global collaboration with AbbVie to…

AbbVieduvelisibInfinity PharmaceuticalsIPI-145LicensingOncologyPharmaceutical

AbbVie 2nd-qtr 2014 earnings beat forecasts

25-07-2014

US drugmaker AbbVie, which has just clinched a $55 billion deal to acquire Ireland-based Shire, reported…

AbbVieFinancialHumiraPharmaceutical

Shire’s strong 2nd-qtr financials justify holding out for higher AbbVie bid

Shire’s strong 2nd-qtr financials justify holding out for higher AbbVie bid

18-07-2014

Ireland-headquartered drugmaker Shire, which has just accepted an increased $54 billion bid from the…

AbbVieFinancialIrelandPharmaceuticalShire

Shire finally accepts AbbVie’s takeover offer

Shire finally accepts AbbVie’s takeover offer

18-07-2014

After a protracted and at times hostile courtship, Ireland-headquartered drugmaker Shire has finally…

AbbVieHumiraMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

Shire succumbs to AbbVie’s yet again increased offer of £53.20 per share

14-07-2014

Ireland-headquartered Shire, which just on Friday confirmed it had finally entered talks with suitor…

AbbVieAdalimumabFinancialIrelandMergers & AcquisitionsPharmaceuticalShireUSA

Shire confirms it has entered into talks with AbbVie

Shire confirms it has entered into talks with AbbVie

12-07-2014

Following reports by the Bloomberg news service, on Friday Ireland-based drugmaker Shire confirmed that…

AbbVieIrelandMergers & AcquisitionsNeurologicalPharmaceuticalRare diseasesShireUSA

AbbVie comes up with higher offer for Shire of $51.5 billion

AbbVie comes up with higher offer for Shire of $51.5 billion

08-07-2014

As has been widely expected following the meetings last week with major shareholders of Ireland headquartered…

AbbVieMergers & AcquisitionsPharmaceuticalShire

AbbVie justifies its position regarding Shire offer

AbbVie justifies its position regarding Shire offer

26-06-2014

US drugmaker AbbVie has set out its ‘strategic rationale’ for its proposal to buy Ireland headquartered…

AbbVieFinancialPharmaceuticalShire PharmaceuticalsUSA

AbbVie raises expectations driven by strong performance

AbbVie raises expectations driven by strong performance

24-06-2014

US drugmaker AbbVie has raised the midpoint of its full-year 2014 earnings-per-share guidance by six…

AbbVieAmortizationBusiness FinanceFinanceFinancialGuidancePharmaceuticalUSAUSD

Analysts view Shire defense as independent pharma

Analysts view Shire defense as independent pharma

24-06-2014

There has been quite a lot of reaction to yesterday’s presentation by Ireland-headquartered Shire's…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire sets out robust defense for rejecting AbbVie takeover bid

Shire sets out robust defense for rejecting AbbVie takeover bid

23-06-2014

Ireland-headquartered Shire today presented a robust defense of its position as an independent pharmaceutical…

AbbVieMergers & AcquisitionsPharmaceuticalShire

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

Shire rejects unsolicited $46.5 billion takeover offer from AbbVie

20-06-2014

Ireland headquartered Shire has this morning revealed that it has received, and rejected, an unsolicited…

AbbVieMergers & AcquisitionsPharmaceuticalShire

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

EMA validates Marketing Authorization Applications for AbbVie’s hepatitis C treatment

17-06-2014

US drugmaker AbbVie announced today that the Marketing Authorization Applications (MAAs) for its investigational,…

AbbVieAnti-viralsPharmaceuticalRegulationRitonavir TabletsUSA

Biogen and AbbVie release Phase III data for MS treatment

Biogen and AbbVie release Phase III data for MS treatment

17-06-2014

US biotech firm Biogen Idec and US drugmaker AbbVie have announced positive top-line results from the…

AbbVieBiogen IdecCNS DiseasesdaclizumabPharmaceuticalResearchUSA

Positive association between adherence and anti-TNF therapy compared to conventional therapy

Positive association between adherence and anti-TNF therapy compared to conventional therapy

11-06-2014

US drugmaker AbbVie has released results from its multi-country ALIGN study, which shows that across…

AbbVieAnti-Arthritics/RheumaticsHealthcareInflammatory diseasesPharmaceutical

AbbVie opens expanded manufacturing facility in Ireland

AbbVie opens expanded manufacturing facility in Ireland

03-06-2014

The chairman and chief of US drugmaker AbbVie, Richard Gonzalez, accompanied by other senior executives,…

AbbVieAnti-viralsFinancialIrelandPharmaceuticalProduction

AbbVie files for Canadian approval of all-oral, interferon-free hepatitis C therapy

22-05-2014

US drugmaker AbbVie has filed a New Drug Submission to Health Canada seeking approval for its investigational,…

AbbVieAnti-viralsCanadaPharmaceuticalRegulation

AbbVie gains FDA orphan designation for Humira in uveitis

21-05-2014

The US Food and Drug Administration granted US drugmaker AbbVie’s blockbuster rheumatoid arthritis…

AbbVieHumiraOphthalmicsPharmaceuticalRegulationUSA

Breakthrough designation for B-MS/AbbVie’s MM drug elotuzumab

19-05-2014

The US Food and Drug Administration has granted elotuzumab, an investigational humanized monoclonal antibody…

AbbVieBristol-Myers SquibbelotuzumabOncologyPharmaceuticalRegulationUSA

1 to 25 of 86 results

Back to top